ARWR
Arrowhead Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +10.0% ·
share flow +11.4% ·
net new positions +9.1%
— formula
Broad accumulation — rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 131 | +6 | 82.23M | $6.28B | +14 | −9 |
| Q1 2026 | 129 | +9 | 82.68M | $4.92B | +14 | −6 |
| Q4 2025 | 119 | +2 | 83.16M | $5.52B | +3 | — |
| Q3 2025 | 18 | 0 | 61.93M | $2.14B | +1 | −2 |
| Q2 2025 | 16 | +2 | 54.75M | $865.08M | +2 | — |
| Q1 2025 | 11 | +1 | 14.99M | $191.04M | +1 | — |
| Q4 2024 | 10 | -1 | 13.46M | $253.12M | +1 | −2 |
| Q3 2024 | 10 | +1 | 7.88M | $152.69M | +1 | — |
| Q2 2024 | 9 | — | 6.44M | $167.29M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 7.00M | +16.3% | $89.17M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 2.95M | -0.2% | $37.60M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 3 | Norges Bank ✦ (passive) | 1.80M | -12.3% | $22.96M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 986.95K | +168.2% | $12.57M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | Two Sigma Investments ✦ | 835.17K | +5.1% | $10.64M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Millennium Management ✦ | 690.80K | -24.5% | $8.80M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 7 | Fisher Asset Management ✦ | 483.25K | +238.1% | $6.16M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | T. Rowe Price ✦ | 93.19K | +22.9% | $1.19M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 9 | Marshall Wace ✦ | 59.76K | -31.0% | $761,343 | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | Wellington Management ✦ | 52.61K | -5.0% | $670,302 | 0.0% | ▼ Trim | 4 | SEC ↗ ×4 |
| 11 | AQR Capital Management ✦ | 40.51K | New | $513,616 | 0.0% | New | 1 | SEC ↗ ×5 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| AQR Capital Management | $513,616 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 430 holders, 120.06M shares, $7.40B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 2.00K sh · $173,920
Director · 11.60K sh · $1.01M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology